| Authors: |
Sakakibara N; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States., Clavijo PE; Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States., Sievers C; Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States., Gray VC; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States., King KE; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States., George AL; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States., Ponnamperuma RM; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States., Walter BA; Genitourinary Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, MD, United States., Chen Z; Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States., Van Waes C; Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States., Allen CT; Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD, United States., Weinberg WC; Office of Biotechnology Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, United States. |
